학술논문
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia May 2024
Subject
Language
ISSN
2152-2650